Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sarika Savajiyani

Pulmonary Disease Little Rock, AR Doctor of Osteopathy

NPI 1649531013 CMS profile 752330

10001 Lile Dr, Little Rock, AR 72205

Open in the dashboard

General payments

$2,540

106 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sarika Savajiyani of Little Rock, AR is reported in the CMS Open Payments database as having received $2,540 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $52 1
2023 General $84 4
2022 General $621 28
2021 General $1,031 41
2020 General $189 8
2019 General $563 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarika Savajiyani
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Sarika Savajiyani were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Sarika Savajiyani Pulmonary Disease median Middle half National median
2019 $563 $377 $109–$1,340 $163
2020 $189 $230 $56–$907 $114
2021 $1,031 $269 $68–$1,072 $132
2022 $621 $390 $100–$1,457 $149
2023 $84 $419 $114–$1,659 $160
2024 $52 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $414 20 payments
  2. Philips Electronics North America Corporation $307 12 payments
  3. United Therapeutics Corporation $235 6 payments
  4. GlaxoSmithKline, LLC. $231 14 payments
  5. Abiomed $149 1 payment
  6. Actelion Pharmaceuticals US, Inc. $146 2 payments
  7. Grifols USA, LLC $138 6 payments
  8. AbbVie, Inc. $119 3 payments
  9. La Jolla Pharmaceutical Company $106 4 payments
  10. Regeneron Healthcare Solutions, Inc. $101 3 payments
  11. Other $593 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,540 106 payments
Products named General payments · program years 2019–2024
  1. OFEV $212 11 payments
  2. TYVASO $199 4 payments
  3. SPIRIVA RESPIMAT $176 8 payments
  4. STIOLTO RESPIMAT $155 6 payments
  5. Impella $149 1 payment
  6. inCourage $140 6 payments
  7. Prolastin-C Liquid $138 6 payments
  8. ORENITRAM $137 4 payments
  9. TRELEGY ELLIPTA $132 8 payments
  10. GIAPREZA $106 4 payments
  11. Other $1,343 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$91,850

Medicare's payments for the services billed

Medicare patients

224

Average age 74

Services billed

870

111 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 73%
Atrial fibrillation 55%
Chronic kidney disease 51%
COPD 51%
Arthritis 51%
Diabetes 48%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record